Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Efficacy and Safety of ALKS 9072 (Also Known as Aripiprazole Lauroxil, ALKS 9070, or ARISTADA) in Subjects With Schizophrenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of schizophrenia according to DSM-IV-TR criteria~* Has been able to achieve outpatient status for more than 3 months in the past year~* Body mass index (BMI) of 18.5 to 40.0 kg/m2 (inclusive)~* Resides in a stable living situation~* Willing and able to be confined to an inpatient study unit for 2 weeks or longer~Exclusion Criteria:~* History of poor or inadequate clinical response to treatment with aripiprazole~* History of treatment resistance~* Known or suspected intolerance of, allergy, or hypersensitivity to aripiprazole, its ingredients, other antipsychotic agent, or INTRALIPID (including peanuts, soy, egg, or glycerol)~* Diagnosis of current substance dependence (including alcohol)~* Pregnant, lactating, or breastfeeding~* Receipt of any antipsychotic medication by IM injection within 60 days before Screening~* Current involuntary hospitalization or incarceration~* Hospitalized for more than 30 days during the 90 days before Screening~Additional inclusion/exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- ALKS 9072 (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).